CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
Xavier Pivot(Levi Strauss (United States)), Semiglazov Vf(Institute of Oncology NN Petrov), Zurawski Bogdan(Centrum Onkologii), Stefania Gori(Ospedale Sacro Cuore Don Calabria), Magdolna Dank(Semmelweis University), Ramona F. Swaby(Merck & Co., Inc., Rahway, NJ, USA (United States)), Fareha Nagi(Friedrich-Ebert-Stiftung e.V.), Alessandra Fabi(Agostino Gemelli University Polyclinic), Arnd Nusch(Centrum Onkologii), Stephen Chan(Heidelberg University), R. Allerton, Sergio Santillana, Alexey Manikhas(Centrum Onkologii), Eva Ciruelos(Hospital Universitario 12 De Octubre), Roma Parikh(Karolinska University Hospital), Bogusława Karaszewska(State University of Applied Sciences in Konin), Paolo Bidoli(Fondazione IRCCS Istituto Nazionale dei Tumori), Lajos Hornyák(Hospital Universitario 12 De Octubre), Ewa Chmielowska(Centrum Onkologii), Sara Margolin(University of Copenhagen), Michelle DeSilvio(Newark Beth Israel Medical Center)
Cited by 253
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k